Endologix Announces Exclusive Distributor Agreement with Boston Scientific for the Chinese Market

Endologix, Inc. announced an agreement naming Boston Scientific Corporation (NYSE: BSX) the exclusive distributor for Endologix products in China. The long-term agreement includes distribution rights to Endologix’s current EndoVascular Aneurysm Repair (EVAR) and Endovascular Aneurysm Sealing (EVAS) products, as well as the right of first negotiation for future product offerings by Endologix.

“We are excited to partner with Boston Scientific to bring next-generation abdominal aortic aneurysm solutions to patients in China,” said John Onopchenko, Chief Executive Officer of Endologix, Inc. “China is one of the largest and fastest-growing EVAR markets in the world, representing an exciting market opportunity for Endologix. We look forward to building our brand in this important market by leveraging the Boston Scientific team’s extensive experience introducing new products for patients suffering from vascular disease.”

As part of the agreement, Boston Scientific plans to invest in building a dedicated sales team to commercialize the Endologix products and drive adoption. Additionally, Endologix will provide commercial and clinical support and training to the Boston Scientific team, with the goal of ensuring that the best possible clinical outcomes are realized. Boston Scientific expects to begin selling these products upon local regulatory approval and subsequent commercial launch of the first product, anticipated in 2021.

The current portfolio of Endologix products includes the Ovation® iX Abdominal Stent Graft and the AFX2® Endovascular Abdominal Aortic Aneurysm System, both of which are minimally-invasive solutions to repair aortic aneurysms and have received U.S. FDA clearance and CE mark.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company’s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once an AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. For more information, visit www.endologix.com.

Leave a Reply

Your email address will not be published. Required fields are marked *